Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2C192 and CYP2C1917 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.

Scientific reports - 10 Aug 2017

Damkier Per, Kjærsgaard Anders, Barker Kimberly A, Cronin-Fenton Deidre, Crawford Anatasha, Hellberg Ylva, Janssen Emilius A M, Langefeld Carl, Ahern Thomas P, Lash Timothy L

Abstract excerpt

The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen treatment of breast cancer is subject to substantial interest and controversy. CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer. We used outcome and genotyping data from the large publicly available International...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cytochrome P-450 CYP2C19

Share to Neoplasm Recurrence, Local

Share to Pharmacogenetics

Share to Proportional Hazards Models

Share to Tamoxifen

Source

Open in PubMed Open full text

Identifiers

PMID: 28798474
DOI: 10.1038/s41598-017-08091-x
PMCID: PMC5552748

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset.PMID 28798474Read ↗

Effect of CYP2C19 genotypes on tamoxifen metabolism and early-breast cancer relapse.Semantic proximity Read ↗

The CYP2C19*2 genotype predicts tamoxifen treatment outcome in advanced breast cancer patients.Semantic proximity Read ↗

Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.Semantic proximity Read ↗

Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.Semantic proximity Read ↗

CYP2C19*2 polymorphism is associated with increased survival in breast cancer patients using tamoxifen.Semantic proximity Read ↗

CYP2C19*17 is associated with decreased breast cancer risk.Semantic proximity Read ↗

CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.Semantic proximity Read ↗

Association of CYP2C19*2 and associated haplotypes with lower norendoxifen concentrations in tamoxifen-treated Asian breast cancer patients.Semantic proximity Read ↗

Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.Semantic proximity Read ↗

Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen TherapySemantic proximity Read ↗

Effect of CYP2D6 polymorphisms on breast cancer recurrence.Semantic proximity Read ↗

SULT1A1, CYP2C19 and disease-free survival in early breast cancer patients receiving tamoxifen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.